
Thermo Fisher Scientific APOC2 Polyclonal Antibody
APOC2 단백질을 인식하는 Thermo Fisher Scientific의 토끼 폴리클로날 항체. Western blot 및 IHC(P) 적용 가능. 인간, 마우스, 랫트 반응성. 친화 크로마토그래피로 정제된 액상 항체로, -20°C에서 보관. 연구용 전용 시약.
- 카탈로그번호
- PA5102480
- 판매단위
- pk
카탈로그
1개 옵션 · 카탈로그 번호를 클릭하면 복사됩니다Thermo Fisher Scientific · Thermo Fisher Scientific APOC2 Polyclonal Antibody
Applications and Tested Dilution
| Application | Tested Dilution | Publications |
|---|---|---|
| Western Blot (WB) | 1:500–1:2,000 | View 3 publications |
| Immunohistochemistry (Paraffin) (IHC (P)) | 1:50–1:200 | - |
Product Specifications
| 항목 | 내용 |
|---|---|
| Species Reactivity | Human, Mouse, Rat |
| Published Species | Mouse |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen | A synthesized peptide derived from human APOC2 (Accession P02655), corresponding to amino acid residues G2–K52 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Concentration | 1 mg/mL |
| Purification | Affinity chromatography |
| Storage Buffer | PBS, pH 7.4, with 50% glycerol |
| Contains | 0.02% sodium azide |
| Storage Conditions | -20°C |
| Shipping Conditions | Wet ice |
| RRID | AB_2851882 |
Product Specific Information
Antibody detects endogenous levels of total APOC2.
Target Information
Apolipoproteins are protein components of plasma lipoproteins.
The apolipoprotein C gene family encodes four homologous proteins (apoC-I to apoC-IV) that modulate the metabolism of triglyceride-rich lipoproteins.
The human apoC-I gene maps to chromosome 19q13.2 and is expressed primarily in the liver, activated during monocyte differentiation into macrophages.
The human apoC-II gene, also on chromosome 19q13.2, encodes a 79-amino-acid single-chain protein that serves as a cofactor for lipoprotein lipase, which hydrolyzes plasma triglycerides and transfers fatty acids to tissues.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Thermo Fisher Scientific 상품 둘러보기
전체보기문의
0개 · 배송·재고 문의는 실시간 상담이 빠릅니다아직 등록된 문의가 없어요.
